Transgene SA · EURONEXT:TNG
Transgene SA — Investor Presentation (June 2019)
36 slides from Transgene SA's investor presentation, Jun 4, 2019
Slide 1: Virus-based immunotherapies to transform the fight against solid tumors
Virus-based immunotherapies to transform the fight against solid tumors June 2019
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be
Slide 3: Our Collaboration with AstraZeneca
NEW! Our Collaboration with AstraZeneca 3
Slide 4: Collaboration and License Option Agreement to Develop Novel OVs
Collaboration and License Option Agreement to Develop Novel OVs • 5 novel oncolytic immunotherapies will be developed, integrating: - Transgene Invir.IO™ based oncolytic viruses (improved TK-RR- proprietary virus) - Potent therapeutic payloads to be encoded in the OV • Transgene to receive $10 milli
Slide 5: Significant Press Coverage
Significant Press Coverage “AstraZeneca ties up with “Transgene's armed “AstraZeneca adds oncolytic France's Transgene to oncolytic virus technology virus option through develop viral draws AZ in potential five- Transgene deal” immunotherapies” product deal” “Cancers: Transgene et “AZ Targets Viral
Slide 6: Virus-based immunotherapies to transform the fight against solid tumors
Virus-based immunotherapies to transform the fight against solid tumors 6
Slide 7: Clear need to improve treatment options for solid tumors
Clear need to improve treatment options for solid tumors Immune checkpoint blockade – reshaping solid tumor therapy Commonly used as standard of care for various solid cancers However only effective in patients with a pre-existing immune response to their cancer and whose tumors are inflamed (‘hot t
Slide 8: Our Target Market Opportunity
Our Target Market Opportunity • Global immunotherapy market for solid tumors worth $57bn in 2016 • Market estimated to reach $144bn by 2023, growing 14% annually* Immunotherapy eligible patients Immunotherapy eligible patients CURRENTLY FUTURE Immune Checkpoint Immune Checkpoint responsive Non-respo
Slide 9: Cutting-edge molecular virology applied to solid tumors
Cutting-edge molecular virology applied to solid tumors • Next-generation of multifunctional oncolytic viruses (OV) • Individualized virotherapy based on patient’s own based on a more potent OV tumor mutations called neoantigens • Potential to express a range of anti-cancer weapons to • Expected to
Slide 10: Current clinical pipeline
Current clinical pipeline Partner Preclinical Clinical Phase Market Product Indication Phase 1 Phase 2 Phase 3 THERAPEUTIC VACCINES TG4010 Non-small cell lung cancer – 1st line * + nivolumab (ICI) + CT Recurrent HPV-positive head and neck TG4001 cancers * + avelumab (ICI) TG1050 Chronic hepatitis B
Slide 11: Highlights - Positioning Transgene for an exciting 2019
Highlights - Positioning Transgene for an exciting 2019 Significant progress with our key late stage clinical products – set Key clinical results to deliver multiple clinical data readouts in H2 2019 Progress of our novel oncolytic virus platform ➢ Positive data from collaboration with BioInvent pre
Slide 12: Our clinical products are making good progress
Our clinical products are making good progress Important clinical data readouts expected in 2019 12
Slide 13: TG4010 | Our lead therapeutic vaccine in lung cancer
TG4010 | Our lead therapeutic vaccine in lung cancer MVA based therapeutic vaccine targeting the MUC1 TAA ➢ Being developed for the treatment of non-small cell lung cancer (NSCLC) Current lung cancer treatment landscape • Need to increase response rate and OS • Better therapeutic options still neede
Slide 14: TG4010 | Compelling lung cancer clinical data
TG4010 | Compelling lung cancer clinical data Improved response rate & duration of response Successful Phase 2b trial in combination with chemotherapy for 1st line NSCLC Overall survival (months), Patients with non sq. tumors (n=196) TG4010 Placebo + CT + CT Non-squamous (n) 98 98 ORR 40% 28% Median
Slide 15: TG4010 1L | Triple combination regimen in low PD-L1 NSCLC
TG4010 1L | To increase ORR with triple combination regimen in patients with non sq. NSCLC expressing low levels of PD-L1 (<50%) In collaboration with Endpoints • Primary endpoint: objective response rate (ORR) • Secondary endpoints: duration of response, disease control Study rate, progression-free
Slide 16: TG4001 | Current treatments for recurrent/metastatic HNSCC
TG4001 | Current treatments for recurrent/metastatic HNSCC MVA based therapeutic vaccine expressing HPV 16 E6 and E7 oncoproteins First-line therapy Dismal prognosis • For patients with good performance status: historically platinum- based doublet Better therapeutic options (eg. Cisplatin/5-FU or ca
Slide 17: TG4001 | HPV-positive cancers including Head & Neck Cancers
TG4001 | HPV-positive cancers including Head & Neck Cancers Phase 1b/2 in combination with avelumab (Bavencio®) In collaboration with Endpoints (Phase 2 part) • Primary endpoint: Objective response rate (ORR) • Secondary endpoints: progression-free survival (PFS), overall survival (OS), duration of
Slide 18: Pexa-Vec | Most advanced oncolytic virus program
Pexa-Vec | Most advanced oncolytic virus program Engineered oncolytic vaccinia virus armed with a GM-CSF gene that promotes an anti-tumor immune response Global Transgene owns development clinical development plan and commercialization rights in Europe HCC 1L Other solid tumors Licensor: SillaJen •
Slide 19: Pexa-Vec | Large unmet medical need in HCC
Pexa-Vec | Large unmet medical need in HCC First-line therapy • Sorafenib - modest activity │ORR: 2% ; median OS: 10.7 months Dismal prognosis • Lenvatinib recently approved with non-inferiority results (USA, EU, Japan) • Nivolumab could become a new therapeutic option (Phase 3 ongoing) Better thera
Slide 20: Pexa-Vec | Clinical development plan in HCC - 1st line
Pexa-Vec | Clinical development plan in HCC - 1st line Pivotal Phase 3 and combination Phase 2 ➔Position Pexa-Vec with current and future standard of care Advanced HCC Conducted by Advanced HCC Pexa-Vec Sponsor Pexa-Vec 1st line 1st line + Opdivo® + sorafenib Phase 1/2 (nivolumab) Phase 3 • Multi-ce
Slide 21: Our next generation of oncolytic therapeutics
Our next generation of oncolytic therapeutics Multifunctional OVs based on our industry leading large capacity Vaccinia Virus (VV) backbone
Slide 22: Oncolytic viruses | Three complementary ways to act on the tumor
Oncolytic viruses | Three complementary ways to act on the tumor Oncolysis Specific replication in tumor cells, and direct lysis of infected cells Immune response Induction of immunogenic cell death, engagement of both innate and adaptive anti-tumor immunity Immuno-modulating payloads delivery Many
Slide 23: TG6002 | In Phase 1/2a study in GI cancer (IV route)
TG6002 | In Phase 1/2a study in GI cancer (IV route) Viral oncolysis + local production of chemotherapy (5-FU) Gastro-intestinal adenocarcinoma with liver metastasis (colon cancer) (Tumors known to be 5-FU sensitive) Protocol Regimen • Multi-center Phase 1/2a trial • TG6002 IV: D1, D8, D15 + 200 m
Slide 24: Multifunctional OVs to modulate the tumor micro-environment
Multifunctional OVs to modulate the tumor micro-environment Immuno-armed oncolytic viruses based on the improved vaccinia virus Excellent oncolytic activity and induction of strong immunogenic Efficacy tumor cell deaths boosting both innate and adaptive responses Flexible Large genome capacity to
Slide 25: Generate a large portfolio of multifunctional immunotherapies
Generate a large portfolio of multifunctional immunotherapies aimed at modulating the tumor micro-environment Chemokines Multiple options Favoring tumor infiltration 5 undisclosed targets for immune Undisclosed sdAbs modulation of Unlocking local immunosuppression Collaboration with the tumor micro-
Slide 26: OV encoding for anti-CTLA-4 mAb in collaboration with BioInvent
OV encoding for anti-CTLA-4 mAb in collaboration with BioInvent Building a potent multifunctional OV ➢ Improved efficacy compared to combination of separate Ab and OV (1) ➢ Longer duration of expression ➢ Expected improved tolerability owing to lower systemic antibody exposure in peripheral non-tum
Slide 27: Creating individualized immunotherapies leveraging our MVA based platform
Creating individualized immunotherapies leveraging our MVA based platform First clinical trials in Q4 2019
Slide 28: Individualized immunotherapy targets the patient's own neoantigens
| Individualized immunotherapy Targets the patient’s own neoantigens Individualized Based on the patient’s own cancer mutations Efficacy Neoantigens are more immunogenic Safety Established therapeutic class Flexible Versatile platform and AI integration immunotherapy MVA-based therapeutic vaccine
Slide 29: Process for individualized neoantigen vaccination
| Process for individualized neoantigen vaccination combines bioengineering and digital transformation Data processing, Gene editing, Gene sequencing Treatment Artificial intelligence Manufacturing 1. Routine 2. Next 3. Comparison 4. Vaccine 5. Viral Patient generation and selection of generation
Slide 30: NEC | An ambitious partner committed to develop AI in the IO field
NEC | An ambitious partner committed to develop AI in the IO field 30
Slide 31: Our lead candidate TG4050 to enter the clinic in Q4 2019
| Our lead candidate TG4050 to enter the clinic in Q4 2019 • Neoantigen therapeutic vaccine developed for individual patients TG4050 • Based on specific mutations identified in the patient’s own tumor In collaboration with Support of international KOLs Primary endpoints: After surgery Safety and imm
Slide 32: Outlook
Outlook On track to deliver multiple value-enhancing clinical data readouts and preclinical milestones
Slide 33: Company funded to deliver multiple value generating milestones
Company funded to deliver multiple value generating milestones Key figures Key shareholders As of the end of April, 2019 Financial visibility extended to Q4 2020 (incl. €20m credit facility and $10m from AZ deal) Cash and cash equivalents 57 % € 9.1 million as of March 31, 2019 Free float 43 % € 15-
Slide 34: Key news flow for 2019/2020 to deliver value
Key news flow for 2019/2020 to deliver value • Initiate clinical trial of our first candidate (OV encoding for anti-CTLA-4) in H1 2020 • Select second clinical candidate – new construct using our unique VV backbone • Progress with the AstraZeneca collaboration TG4050 - Initiate two clinical trials b
Slide 35: Portfolio to deliver significant news flow over the coming 12-18 months
Portfolio to deliver significant news flow over the coming 12-18 months • TG4010 1L NSCLC: Primary endpoint analysis (ORR) on 35 patients Q1 2020 • Pexa-Vec + nivo 1L HCC: Interim analysis (ORR) on 15 patients • Pexa-Vec Phase 3 1L HCC: Futility analysis H2 2019 • TG4001 HPV+ cancers: First efficacy
Slide 36: Contact
Contact Lucie Larguier Director Corporate Communication and Investor Relations +33 3 88 27 91 04 / +33 6 76 24 72 27 larguier@transgene.fr / investorrelations@transgene.fr @TransgeneSA Transgene 400 Boulevard Gonthier d’Andernach - Parc d’Innovation - CS80166 67405 Illkirch Graffenstaden Cedex Franc